A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Sponsor:
- UroGen Pharma, Inc.
- Sponsor Study ID:
- UT002
- CTO #:
- 104174
- NCT Number:
- NCT06774131
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Bladder
- Study Objectives:
- To evaluate the tumor ablative effect of UGN-104, a novel formulation of UGN-101, in patients with LG-UTUC. To evaluate the durability of response with respect to DOR and DCR rate at scheduled disease assessment time points.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Tsivian, Matvey, at tsivian@musc.edu .
- Study Coordinator, Tucker, Renee, at tuckerr@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina